KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medicine and Oncology / 2021 / Cilt: 5 - Sayı: 4

Atypical Chronic Myeloid Leukemia: Case Report and Review of Literature

Brittany Miles
Nicholas Martinez
Khaled Atieh
James Mackey
Sayfa
358–360
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Without an actionable driver mutation, hypomethylating agents are an emerging treatment option based on four reports showing complete hematologic remission in 7 of 8 patients treated with decitabine.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Atypical chronic myeloid leukemia (aCML) is a BCR-ABL1 negative myelodysplastic/myeloproliferative (MDS/MPN) neoplasm.
📊
Temel Bulgular & Veri:Patients typically present with elevated neutrophil counts and hypercellular bone marrow, but there are no specific genetic or molecular markers available to diagnose aCML and it is therefore a diagnosis of exclusion.
💡
Sonuç & Katkı:Without an actionable driver mutation, hypomethylating agents are an emerging treatment option based on four reports showing complete hematologic remission in 7 of 8 patients treated with decitabine.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Atypical chronic myeloid leukemia (aCML) is a BCR-ABL1 negative myelodysplastic/myeloproliferative (MDS/MPN) neoplasm. Patients typically present with elevated neutrophil counts and hypercellular bone marrow, but there are no specific genetic or molecular markers available to diagnose aCML and it is therefore a diagnosis of exclusion. Atypical CML is rare and carries a poor prognosis, and there is currently no standard of care for treatment. In the absence of an available clinical trial, current consensus is for patients with a suitable donor to undergo allogeneic stem cell transplantation, and a comprehensive evaluation for driver mutations should be performed to screen for the potential use of targeted agents. Without an actionable driver mutation, hypomethylating agents are an emerging treatment option based on four reports showing complete hematologic remission in 7 of 8 patients treated with decitabine.

🔖

Bu Makaleye Atıf Yap

Miles, B., Martinez, N., Atieh, K., Mackey, J. (2022). Atypical Chronic Myeloid Leukemia: Case Report and Review of Literature. Eurasian Journal of Medicine and Oncology, Cilt: 5 - Sayı: 4, 358–360. https://ajindex.com/articles/509496

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Vardiman JBR, Arber DA. Introduction and overview of the classification of myeloid neoplasms. In: Swerdlow SCE, Harris NL, editors. International Agency for Research on Cancer, WHO classification of tumours of haematopoietic and lymphoid tissue. 4th ed. Geneva: WHO; 2008. p. 18–30
  2. Zoi K, Cross NCP. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int J Hematol 2015;101:229–42
  3. Tiu RV, Sekeres MA. Making sense of the myelodysplastic/ myeloproliferative neoplasms overlap syndromes. Curr Opin Hematol 2014;21:131–40
  4. Saqlain N, Ahmed N. Atypical chronic myeloid leukemia, BCRABL1 negative, in a 5-month baby – a rare presentation. J Coll Physicians Surg Pak 2016;26:103–5
  5. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019;33:74–81
  6. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014;123:2645–51
  7. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52
  8. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a longterm analysis of 12 cases and a critical review of the literature. Leukemia 2005;19:313–7
  9. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, et al. Activity of azacitidine in chronic myelomonocytic leuke mia. Cancer 2011;117:2690–6
  10. Kong JH, Nam H, Go T-H, Hyun SY, Shim KY. Characteristics and survival of patients with atypical chronic myeloid leukemia. Blood Res 2019;54:233–6
  11. Itonaga H, Ota S, Ikeda T, Taji H, Amano I, Hasegawa Y, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. Leuk Res 2018;75:50–7
  12. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009;7:e59
  13. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sc